FDA Briefing Documents Recommend Against Adding BPC-157, TB-500, and MOTS-c to 503A Compounding List

The peptide compounding world is bracing for what could be a defining regulatory moment. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will convene at the FDA White Oak Campus in Silver Spring, Maryland, to deliberate on whether seven research peptides should be recommended for addition to the 503A Bulk Drug Substances List. But in a development that has sent shockwaves through the compounding industry, FDA's pre-meeting briefing documents, made public in advance of the committee sessions as is standard procedure, recommend that the agency not add any of the seven peptides to the list.

The seven compounds under review are BPC-157 (free base and acetate), KPV (free base and acetate), TB-500 (free base and acetate), MOTS-c (free base and acetate), Emideltide (DSIP), Semax, and Epitalon. For each one, FDA's briefing documents reach the same conclusion: the available evidence does not support the safety profile needed for inclusion on the 503A list under current standards.

Background: How These Peptides Got Here

This review is the product of a regulatory journey that began years earlier and accelerated dramatically in early 2026. In late 2023, the FDA had placed 19 peptides in "Category 2" status, a designation indicating significant safety concerns that precluded consideration for the 503A Bulk Substances List. Category 2 effectively barred compounding pharmacies from using these compounds unless they were included on other approved lists.

The trajectory changed with announcements from HHS Secretary Robert F. Kennedy Jr. in April 2026. Under RFK Jr.'s direction, HHS removed 12 peptides from Category 2, clearing the path for PCAC to evaluate them for potential 503A inclusion. The July meeting is the result of that removal: for the first time, these peptides are in the formal review pipeline.

But being removed from Category 2 does not mean approval. The PCAC process is distinct: the committee evaluates nominations submitted to FDA's bulk drug substances list, weighs the available evidence on safety and efficacy, and makes non-binding recommendations. The FDA then decides whether to proceed with rulemaking to formally add compounds to the list, a process that itself requires notice-and-comment and can take over a year.

What the Briefing Documents Say

FDA's pre-meeting briefs are detailed technical assessments, and for each of the seven peptides, the agency applies a consistent analytical framework: Is there adequate evidence that the substance is safe for use in compounding? Are there clinical trials or robust human safety data? Are there concerns about impurities, degradation products, or off-target effects?

For BPC-157, arguably the most studied of the seven, FDA's brief acknowledges the extensive animal literature demonstrating healing and anti-inflammatory properties, but emphasizes the absence of human clinical trial data meeting regulatory standards. BPC-157 has never been through a formal IND process, and the breadth of anecdotal reports in the wellness community does not substitute for controlled human safety data in the FDA's framework. The brief also raises questions about the structural complexity of BPC-157 acetate and the potential for synthesis-related impurities at commercial compounding scale.

TB-500, the synthetic version of thymosin beta-4 fragment, faces a similar evidence gap. While thymosin beta-4 has been investigated by RegeneRx Biopharmaceuticals in clinical trials for wound healing and dry eye, the TB-500 fragment used in compounding is not identical to the investigated compound, and FDA treats them as distinct for regulatory purposes. The brief notes that regulatory-grade safety data specific to TB-500 are lacking.

MOTS-c, a mitochondria-derived peptide studied for metabolic effects in preclinical models, faces the broadest evidentiary gap, it is among the least-studied of the nominees in human subjects, with only a handful of Phase I data points available globally.

KPV, a tripeptide fragment of alpha-MSH with putative anti-inflammatory activity, has some evidence in cell and animal models of inflammatory bowel disease, but clinical data remain sparse.

For Emideltide (DSIP), Semax, and Epitalon, all three have research histories primarily from Eastern European academic literature, much of it from the Soviet-era and early post-Soviet period, which FDA views as insufficient for establishing safety in a U.S. compounding context.

The Stakes for the Compounding Industry

The PCAC vote on July 23 to 24 is non-binding, but it carries significant practical weight. If the committee recommends against inclusion and FDA follows that recommendation through final rulemaking, compounding pharmacies that have been supplying these peptides under various regulatory interpretations would face significant market constraints.

503A pharmacies, traditional compounding pharmacies that compound for specific patient prescriptions, can only compound from bulk drug substances that appear on an FDA-approved list or that are components of approved drug products. If BPC-157 and the other peptides are not added to the 503A list, the formal compounding pathway narrows considerably.

503B outsourcing facilities, which operate under different rules and can compound for office use without patient-specific prescriptions, face analogous limitations on bulk substance usage. Neither pathway remains open for large-scale production if FDA takes a restrictive final position.

Comment Window and Stakeholder Response

FDA opened a public comment window relevant to the PCAC review, with comments submitted by July 9 provided directly to committee members and those submitted by July 22 considered by FDA in its deliberations. The response has been substantial: the compounding industry, patient advocacy groups, and practitioners in the wellness and longevity medicine space have submitted thousands of comments, predominantly in favor of 503A listing.

The American Compounding Pharmacists Association and allied organizations have argued that the lack of formal clinical trials reflects a deliberate regulatory gap, these peptides have not been developed through the IND/NDA process precisely because there is no commercial incentive to invest hundreds of millions in trials for compounds that would be generic or near-generic at approval. They argue that the PCAC framework, if it requires pharmaceutical-grade clinical trials as a prerequisite for 503A consideration, structurally cannot accommodate the category of compounded preparations for which patient access has historically been justified.

What Comes Next

The PCAC recommendation, whatever it is, goes back to FDA for decision. If the committee votes against addition, FDA can still proceed differently, but historically the agency has followed PCAC recommendations in the large majority of cases. If FDA issues a final rule excluding these compounds from the 503A list, affected compounding pharmacies would typically have a 90 to 180 day wind-down period.

For industry observers, the key question is whether RFK Jr.'s deregulatory posture at HHS will translate into FDA action that overrides the technical review. The April 2026 removal from Category 2 was interpreted as a political signal that the current administration favors expanded peptide access. But FDA's briefing documents suggest the agency's technical staff do not view administrative reclassification as a substitute for clinical evidence.

The next three weeks are among the most consequential in recent memory for the peptide compounding sector. Practitioners who prescribe or rely on 503A-compounded peptides, CDMO operators who supply bulk peptide to compounders, and patients using BPC-157 or TB-500 therapeutically all have significant stakes in the outcome.

For staffing implications, both the demand for regulatory affairs specialists familiar with 503A frameworks and the potential workforce contraction at compounding facilities if these peptides are restricted, see related coverage at PeptideStaff on compounding pharmacy staffing and 503B outsourcing facility compliance.